摘要
参考文献 (请在框内滑动浏览)
[1]Wingard JR,Majhail NS,Brazauskas R,et al.Long-term survival and late deaths after allogeneic hematopoietic cell transplantation[J].J Clin Oncol,2011,29(16):2230-2239.
[2]Wong FL,Teh JB,Atencio L,et al.Conditional Survival,Cause-Specific Mortality,and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation[J].J Natl Cancer Inst,2020,112(11):1153-1161.
[3]Lee CJ,Kim S,Tecca HR,et al.Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia[J].Blood Adv,2020,4(6):983-992.
[4]Ringdén O,Brazauskas R,Wang Z,et al.Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning[J].Biol Blood Marrow Transplant,2014,20(11):1777-1784.
[5]Vajdic CM,Mayson E,Dodds AJ,et al.Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation:A Population-Based Cohort Study[J].Biol Blood Marrow Transplant,2016,22(5):949-956.
[6]Del Galy AS,Rousseau A,Capes A,et al.Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation[J].Bone Marrow Transplant,2022,57(9):1365-1372.
[7]Inamoto Y,Matsuda T,Tabuchi K,et al.Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation[J].Blood Adv,2018,2(15):1901-1913.
[8]Armenian SH,Chen Y,Hageman L,et al.Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation:The Results of the BMT Survivor Study[J].J Clin Oncol,2022,40(28):3278-3288.
[9]Yokota A,Ozawa S,Masanori T,et al.Secondary solid tumors after allogeneic hematopoietic SCT in Japan[J].Bone Marrow Transplant,2012,47(1):95-100.
[10]Park SS,Park SH,Han S.Risk of secondary nonhematologic malignancies after allogeneic stem cell transplantation:A nationwide case-control cohort study[J].Int J Cancer,2022,151(7):1024-1032.
[11]Schaar DA,Pirsl F,Holtzman N,et al.Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease[J].Transplant Cell Ther,2021,27(11):937.e1-937.e7.
[12]Santarone S,Natale A,Angelini S,et al.Secondary oral cancer following hematopoietic cell transplantation[J].Bone Marrow Transplant,2021,56(5):1038-1046.
[13]Atsuta Y,Suzuki R,Yamashita T,et al.Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease[J].Ann Oncol,2014,25(2):435-441.
[14]Majhail NS,Brazauskas R,Rizzo JD,et al.Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning[J].Blood,2011,117(1):316-322.
[15]Ehrhardt MJ,Brazauskas R,He W,et al.Survival of patients who develop solid tumors following hematopoietic stem cell transplantation[J].Bone Marrow Transplant,2016,51(1):83-88.
[16]Tichelli A,Beohou E,Labopin M,et al.Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients[J].JAMA Oncol,2019,5(2):229-235.
[17]Chang HA,Armenian SH,Dellinger TH.Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation[J].J Natl Compr Canc Netw,2018,16(2):211-218.
[18]Socie G.Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia[J].JCO,2022,40(28):3235-3238.
[19]Lupo-Stanghellini MT,Piemontese S,Assanelli A,et al.Second Solid Cancers After Hematopoietic Stem Cell Transplantation:Active Surveillance During Long-term Follow-up[J].Hemasphere,2021,5(11):e654.
[20]Cohen A,Rovelli A,Merlo DF,et al.Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation:an EBMT Late Effects Working Party Study[J].J Clin Oncol,2007,25(17):2449-2454.
[21]Friedman DL,Rovo A,Leisenring W,et al.Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation:a report from the FHCRC and the EBMT-Late Effect Working Party[J].Blood,2008,111(2):939-944.
[22]Rizzo JD,Curtis RE,Socié G,et al.Solid cancers after allogeneic hematopoietic cell transplantation[J].Blood,2009,113(5):1175-1183.
[23]Leisenring W,Friedman DL,Flowers MED,et al.Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation[J].J Clin Oncol,2006,24(7):1119-1126.
[24]Herr MM,Curtis RE,Tucker MA,et al.Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation[J].J Am Acad Dermatol,2020,83(3):762-772.
[25]Fasslrinner F,Schetelig J,Burchert A,et al.Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission:retrospective follow-up of an open-label,randomised phase 3 trial[J].Lancet Haematol,2018,5(4):e161-e169.
[26]Baker KS,Leisenring WM,Goodman PJ,et al.Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation[J].Blood,2019,133(26):2790-2799.
本文版权为《临床内科杂志》所有,转载请注明作者和来源。
